Immunoglobulins (Immunoglobulin)

Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.

Also Known As:

Networked: 23980 relevant articles (1108 outcomes, 2055 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Shoenfeld, Yehuda: 32 articles (01/2016 - 07/2002)
2.	Dispenzieri, Angela: 27 articles (05/2015 - 08/2005)
3.	Rezaei, Nima: 25 articles (12/2015 - 12/2003)
4.	Shoenfeld, Y: 23 articles (12/2015 - 01/2000)
5.	Stamatopoulos, Kostas: 23 articles (12/2015 - 07/2004)
6.	Pandey, Janardan P: 23 articles (05/2015 - 06/2002)
7.	Kyle, Robert A: 23 articles (05/2015 - 05/2002)
8.	Aghamohammadi, Asghar: 23 articles (10/2014 - 03/2004)
9.	Rosenquist, Richard: 22 articles (01/2015 - 03/2002)
10.	Burns, Jane C: 21 articles (07/2015 - 02/2003)

Related Diseases

1.	Infection 10/01/1984 - "The MCAs to LPS were highly protective against infection, with 50% protective doses of 0.05-2.5 micrograms of immunoglobulin per mouse. " 01/01/1992 - "An additional key finding was that similar levels of complete protection against lethal infection occurred in guinea pigs receiving partially purified anti-Toxoplasma immunoglobulins or immune cells that had been enriched for B cells prior to transfer. " 01/01/1983 - "Persistence of any residual active infection of the nervous system could be eliminated since as well as fairly rapid restoration of normal CSF cytology and chemistry there was a slow reduction (and sometimes return to normal) of initially very high levels of immunoglobulins G, disappearance of their oligoclonal distribution (3 cases), and negativation of quantitative immunofluorescence serology (F.T.A. " 01/01/2014 - "The aim of this trial study was to assess the preventive efficacy of immunoglobulin with a high titer of anti-CMV antibody for mother-to-fetus cytomegalovirus (CMV) transmission among pregnant women with primary/acute CMV infection. " 09/01/2005 - "Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice."
2.	Hepatitis B 01/01/1982 - "Hepatitis B immunoglobulin is more effective than immune serum globulin. " 10/01/2014 - "New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence." 11/01/2009 - "Hepatitis B immunoglobulin and antiviral therapy was only partially effective in preventing HBV reinfection in patients with HCC recurrence." 01/01/2000 - "The hospital-wide hepatitis B immunisation programme helped to raise the immune status of the staff so as to reduce the costly prophylactic usage of hepatitis B immunoglobulin." 06/09/1989 - "Immunization with a recombinant vaccine without concomitant administration of hepatitis B immunoglobulin, therefore, considerably decreased the incidence of the carrier state."
3.	Thrombocytopenia (Thrombopenia) 11/01/2011 - "She was treated successfully with intravenous immunoglobulin with complete resolution of the thrombocytopenia and no subsequent recurrences." 02/01/1990 - "This thrombocytopenia which had not responded to conventional therapy improved after the third of anti-Rhesus D immunoglobulin infusion, but the efficacy of this treatment could not be proven in this case report. " 09/01/1994 - "High-dose intravenous immunoglobulin was effective in correcting the thrombocytopenia in this second instance. " 09/01/1985 - "In limited experience the administration of high-dose immunoglobulin appears to be effective for antepartum use in patients with immunologic thrombocytopenia. " 10/01/2007 - "Picogram doses of lipopolysaccharide exacerbate antibody-mediated thrombocytopenia and reduce the therapeutic efficacy of intravenous immunoglobulin in mice."
4.	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 11/01/2010 - "Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance." 11/01/2014 - "A sustained clinical efficacy was observed after the switch to subcutaneous immunoglobulin: the Overall Neuropathy Limitation Scale score improved in the group of 66 CIDP patients (P = 0.018), with only one subject reporting a worsening of 1 point, and remained stable in the group of 21 MMN patients (P = 0.841), with one subject reporting a worsening of two points. " 04/14/2009 - "Chronic inflammatory demyelinating polyradiculoneuropathy trials have demonstrated the efficacy of IV immunoglobulin vs placebo. " 01/01/2015 - "Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction." 03/01/2006 - "[Intermittent intravenous immunoglobulin infusion prevented relapses in patients with remission-exacerbation type chronic inflammatory demyelinating polyradiculoneuropathy]."
5.	Neoplasms (Cancer) 10/01/1977 - "It was concluded that the tumor-bearing LOU/Dec rat is an excellent model for studies of immunoglobulin secretion, and the cured, resistant rat is an excellent model for studies of cell mediated immunity." 04/01/1987 - "Mice treated with 50 microCi 90Y-labeled control immunoglobulin had spleens which were twice the normal size and showed extensive areas of erythropoiesis indicative of the presence of tumor foci; in contrast, doses as low as 27 microCi 90Y-labeled specific antibody resulted in complete remission with no microscopic evidence of tumor foci in either spleen or liver. " 08/01/1981 - "Thus, antibody of the appropriate immunoglobulin subclass can be effective in controlling tumor growth if administered in the optimal treatment regimen, but inherent features of the tumor cell ultimately determine whether abrogation or enhancement of growth will occur." 02/01/2002 - "The purified immunoglobulins were effective in the inhibition of endothelial cell proliferation in vitro, and in anti-tumor activity as well as in the inhibition of angiogenesis by adoptive transfer in vivo. " 01/01/1984 - "Tumors could be localized clearly with In-111-labeled specific monoclonal antibody, but improved visualization was obtained after computer-assisted subtraction of the image with Ga-67-labeled nonspecific immunoglobulin. "

Related Drugs and Biologics

1.	Intravenous Immunoglobulins (IVIG)
2.	Immunoglobulin G (IgG)
3.	hepatitis B hyperimmune globulin
4.	Antibodies
5.	Adrenal Cortex Hormones (Corticosteroids)
6.	Antigens
7.	Inosine Triphosphate (ITP)
8.	Immunoglobulin M (IgM)
9.	Immunoglobulin A (IgA)
10.	Prednisolone (Predate)

Related Therapies and Procedures

1.	Plasma Exchange
2.	Liver Transplantation
3.	Aftercare (After-Treatment)
4.	Transplantation (Transplant Recipients)
5.	Drug Therapy (Chemotherapy)